Why Merrill Lynch Sees More Upside in Eli Lilly
Merrill Lynch reiterated a Buy rating and price objective on Eli Lilly after positive data on its Jardiance.
All Work
Chris Lange
Does a Smaller Loss Finally Make AK Steel a Buy?
AK Steel expects the positive financial effects of higher shipments, lower raw material costs, cost reduction efforts and higher operating rates will partially offset lingering low carbon steel spot market prices.
Tracon Pharmaceuticals Surges With Positive Study
Tracon Pharmaceuticals made waves in the market on Friday morning, not so much due to one trial but really one patient who made all the difference.
Texas Instruments Hikes Dividend
Texas Instruments on Thursday announced that it intends to raise its quarterly cash dividend by 12%.
Adobe Rises on Record Quarter
Adobe Systems reported better-than-expected fiscal third-quarter financial results after the markets closed on Thursday.
Nabriva Sets Price for IPO
ThinkstockNabriva Therapeutics A.G. has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding the anticipated price of its initial public offering (IPO) in the U.S. The previous filing set…
Activision’s ‘Taken King’ Sets Otherworldly Records
Activision Blizzard continued on its tear of record-breaking games when it released its newest installment in the Destiny series.
Shopify Rises on New Amazon Collaboration
Shopify announced that it been selected as the preferred migration provider for Amazon Webstore merchants.
Why the Top Aerie Pharma Analyst Sees It Rising Even More
A Canaccord Genuity analyst has a Buy rating on Aerie Pharmaceuticals and increased the price target.
Can-Fite Makes a Comeback With New FDA Designation
Can-Fite BioPharma is building momentum with its most recent designation from the FDA.
What Analysts Have to Say About Under Armour After Investors Day
Under Armour had its Investor Day on Wednesday, and the analysts have cast their votes. Overall the calls were fairly positive.
Achillion Pharma Rises on Solid Interim Results
Its stock has suffered, but it is possible that Achillion’s interim trial results may have put the company back on the right track.
Is Aerie’s Move Sustainable?
Like many other companies in the health care industry, Aerie Pharmaceuticals lives and dies by the FDA's sword.
How Currencies Are Hurting Oracle Earnings
Oracle reported mixed fiscal first-quarter financial results after the markets closed on Wednesday.
RegenXBio Updates Anticipated Price for IPO
This is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy.
Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market
According to Fitch Ratings, biosimilars are beginning to take share from their reference biologics. This is seen in the debut of the first biosimilar drug in the United States.
Why Home Depot Remains an Oppenheimer Top Pick
Brokerage firm Oppenheimer came away from recent meetings with Home Depot senior executives even more confident in its near and longer term positive stance on shares.
SynCardia Updates Terms for IPO
The expected price range for the SynCardia Systems IPO is $10 to $12 for 2.5 million shares.
Meet the Newest Biotech Collaboration: Amgen and Xencor
Amgen and Xencor have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.
Why Oppenheimer Is Less Optimistic About GoPro
While Oppenheimer likes the strides GoPro is making, the firm reiterated a Perform rating due to its more conservative view of the core capture device market.